

***Fiscal Year 2021 Tuberos Sclerosis Complex Research Program
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Exploration – Hypothesis Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>W81XWH-21-TSCRPEHDA</p>	<p>Investigators at all academic levels (or equivalent), including postdoctoral fellows</p>	<ul style="list-style-type: none"> • Supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the tuberous sclerosis complex (TSC) research field. • Projects involving human subjects or human biological substances must be exempt under Title 32 of the Code of Regulations, Part 219.104(d) (32 CFR 219.104(d)) or eligible for expedited review under 21 CFR 56.110. • <i>Preliminary data not required.</i> • Clinical trials not allowed. 	<ul style="list-style-type: none"> • The maximum period of performance is 2 years. • The maximum allowable funding for the entire period of performance is \$150,000 in direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. 	<p>Pre-Application (Letter of Intent): June 17, 2021 5:00 p.m. Eastern time (ET)</p> <p>Application: July 8, 2021 11:59 p.m. ET</p>
<p>Idea Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>W81XWH-21-TSCRPIDA</p>	<p><i>Established Investigators:</i></p> <p>Independent investigators at or above the level of Assistant Professor (or equivalent)</p> <p><i>or</i></p> <p><i>New Investigators:</i></p> <p>Independent investigators at or below the level of Assistant Professor (or equivalent) or Established Investigators in an area other than TSC at or above the level of Assistant Professor seeking to transition to a career in TSC</p>	<ul style="list-style-type: none"> • Promotes ideas that have the potential to yield high-impact findings and new avenues of investigation. • <i>Preliminary data expected.</i> • Clinical trials not allowed. • <i>New Investigator Option</i> supports the continued development of promising independent investigators that are early in their faculty appointments and/or the transition of established investigators from other research fields into a career in the field of TSC research. • Applications from New Investigators and Established Investigators will be peer and 	<ul style="list-style-type: none"> • The maximum period of performance is 3 years. • The maximum allowable funding for the entire period of performance is \$500,000 in direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. 	<p>Pre-Application (Letter of Intent): June 17, 2021 5:00 p.m. ET</p> <p>Application: July 8, 2021 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
		programmatically reviewed separately.		
<p>Clinical Translational Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>W81XWH-21-TSCR-CTRA</p>	<p>Independent Investigators at or above the level of Assistant Professor (or equivalent)</p>	<ul style="list-style-type: none"> • Supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including, diagnosis, prognosis, or treatment of TSC. • Applications may include correlative studies that are associated with a completed clinical trial. • Supports studies advancing clinical trial readiness through development of biomarkers, clinical endpoints, and validation of PK/PD. • Applications may include a small, pilot clinical trial intended to inform the next step in the continuum of translational research. • Preclinical studies may be appropriate but must include a clinical component. • Projects that are exploratory and/or strictly animal research will not be considered for funding. • <i>Preliminary data required.</i> 	<ul style="list-style-type: none"> • The maximum period of performance is 3 years. • The maximum allowable funding for the entire period of performance is \$750,000 in direct costs. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. 	<p>Pre-Application (Letter of Intent): June 17, 2021 5:00 p.m. ET</p> <p>Application: July 8, 2021 11:59 p.m. ET</p>